The European Union Has Announced the Finalized EU GMP Annex 1

The European Union has announced the finalized EU GMP Annex 1 for manufacturing sterile medicinal products. It is creating some reservations for manufacturers who are not certain how these changes may impact their total manufacturing operation and output. In particular, as the August 2023 deadline approaches manufacturers will need to take time to unpack the changes and understand how they will impact their standard operating procedures.

Jennifer Parker, Director of Marketing at Benchmark Products, is advising manufacturers not to wait to consider these new policies. She anticipates the evaluation of SOPs against the guidelines in Annex 1 will require manufacturers to revise and overhaul processes, as well as implement entirely new processes.

Jennifer’s Thoughts:

Although drafts of the new Annex 1 regulations that govern the manufacturers of sterile medicinal products have been circulating for some years now, it still presents a number of challenges when it was actually released in August of this year. Companies will have some barriers when it comes to clients which they will need to meet by the deadline of August next year.

The first one is understanding the complexity of the Annex 1 regulations, being a 50-page document and affecting almost all the areas of production, it will take some time to read, understand, and then evaluate against your own SOPs. And then that’s where I think the biggest challenge is, around evaluating those SOPs against the guidelines. Will you need to rewrite entire operating procedures? Do you need to add new ones where there weren’t any before? And then finally, how are you going to validate your new SOPs? What criteria will you use and the types of products and procedures that you have in place already, will they be sufficient enough to meet the validation criteria?

These are all complex decisions that companies need to make within the deadline. So I really urge manufacturers that are undergoing this process to start early, form a team, and really understand how much work will be involved to get more manufacturing facilities up to compliance.

Follow us on social media for the latest updates in B2B!

Image

Latest

weekly drive-in
Metropolis: Weekly Drive-in
April 15, 2026

Metropolis “Weekly Drive In” reflects a new era of storytelling where AI meets real-world execution, turning everyday field performance into momentum. Centered on genuine conversions and local wins, the series highlights how the company is scaling not just through technology, but through visibility and shared recognition. In an emerging recognition economy, these updates act…

Read More
Drive In, Drive Out: The Rhythm of Metropolis
April 15, 2026

Behind the seemingly mundane choreography of a drive-in lies a broader story about how modern cities script behavior, turning even the simplest actions into rehearsed routines. What looks like repetition is really a quiet testament to systems designed for flow and control, where efficiency often outweighs individuality. In places like Metropolis, the rhythm of…

Read More
telemetry
Visibility at Scale: How Data, Telemetry, and IT Architecture Enable High-Performance Data Centers
April 14, 2026

As AI infrastructure scales at an unprecedented pace, the complexity of managing data center operations has shifted from purely physical challenges to deeply digital ones. Today’s facilities generate enormous volumes of telemetry, and industry estimates suggest hyperscale and AI data centers produce millions of data points per second. At that scale, visibility is no…

Read More
healthcare
The Early-Stage Playbook for Healthcare Founders: Credibility, Founder Mindset, and Real Market Fit
April 13, 2026

Healthcare innovation is having a moment. With over 500 startups applying annually to leading accelerators like Health Wildcatters, the sector is seeing a surge of founders eager to tackle inefficiencies in care delivery, diagnostics, and patient experience. At the same time, digital health is regaining momentum—after a period of market correction, funding went up…

Read More